ANGLE plc Company Profile (LON:AGL)

About ANGLE plc (LON:AGL)

ANGLE plc logoANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:AGL
  • CUSIP: N/A
  • Web:
  • Market Cap: £26.41 million
  • Outstanding Shares: 73,350,000
Average Prices:
  • 50 Day Moving Avg: GBX 39.59
  • 200 Day Moving Avg: GBX 50.05
  • 52 Week Range: GBX 32.27 - GBX 80
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $497,999.00
  • Price / Sales: 53.02
  • Book Value: GBX 0.14 per share
  • Price / Book: 2.57
  • EBIDTA: ($7,070,000.00)
  • Net Margins: -1,326.88%
  • Return on Equity: -61.37%
  • Return on Assets: -60.16%
  • Average Volume: 228,158 shs.

Frequently Asked Questions for ANGLE plc (LON:AGL)

What is ANGLE plc's stock symbol?

ANGLE plc trades on the London Stock Exchange (LON) under the ticker symbol "AGL."

Where is ANGLE plc's stock going? Where will ANGLE plc's stock price be in 2017?

1 brokerages have issued 1 year price objectives for ANGLE plc's stock. Their predictions range from GBX 100 to GBX 100. On average, they anticipate ANGLE plc's stock price to reach GBX 100 in the next twelve months. View Analyst Ratings for ANGLE plc.

Who are some of ANGLE plc's key competitors?

Who are ANGLE plc's key executives?

ANGLE plc's management team includes the folowing people:

  • Andrew D. W. Newland, Chief Executive, Executive Director
  • Ian F. Griffiths, Finance Director, Company Secretary, Executive Director
  • Garth R. Selvey, Non-Executive Chairman of the Board
  • Brian Howlett, Non-Executive Director
  • David W. Quysner CBE, Non-Executive Independent Director

How do I buy ANGLE plc stock?

Shares of ANGLE plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ANGLE plc's stock price today?

One share of ANGLE plc stock can currently be purchased for approximately GBX 36.

MarketBeat Community Rating for ANGLE plc (LON AGL)
Community Ranking:  1.0 out of 5 (star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  106
MarketBeat's community ratings are surveys of what our community members think about ANGLE plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ANGLE plc (LON:AGL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: GBX 100

Analysts' Ratings History for ANGLE plc (LON:AGL)
DateFirmActionRatingPrice TargetDetails
9/11/2017FinnCapReiterated RatingCorporateGBX 100View Rating Details
7/5/2017Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for ANGLE plc (LON:AGL)
No earnings announcements for this company have been tracked by


Earnings Estimates for ANGLE plc (LON:AGL)
Current Year EPS Consensus Estimate: $-10.30 EPS


Dividend History for ANGLE plc (LON:AGL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ANGLE plc (LON:AGL)
Insider Trades by Quarter for ANGLE plc (LON:AGL)
Insider Trades by Quarter for ANGLE plc (LON:AGL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/26/2016Andrew D NewlandInsiderBuy1,350,000GBX 57£769,500
(Data available from 1/1/2013 forward)


Headline Trends for ANGLE plc (LON:AGL)
Latest Headlines for ANGLE plc (LON:AGL)
DateHeadline logoAngle PLC: Exclusive Worldwide Option Over Megakaryocyte Intellectual Property - September 13 at 4:41 PM logoCo-Marketing Partnership with QIAGEN - September 11 at 4:24 PM logoWhy ANGLE Plc (AIM:AGL) Could Be A Buy - September 9 at 3:27 PM logoNew Research with Parsortix - London South East (registration) (blog) - September 4 at 9:15 PM logoAngle PLC Announces New Research With Parsortix Demonstrates Ability to Identify Key Proteins Involved in Breast ... - Benzinga - September 4 at 9:15 PM logoAngle PLC: Preliminary Results - July 27 at 2:59 AM logoPreclinical Study Using Parsortix Presented at Tumor Models Boston Summit - July 20 at 4:33 PM logoANGLE plc (AGL) Set to Announce Earnings on Thursday - July 20 at 1:50 AM logoANGLE plc's (AGL) Speculative Buy Rating Reiterated at Beaufort Securities - June 17 at 11:44 AM logoANGLE plc's (AGL) Speculative Buy Rating Reaffirmed at Beaufort Securities - June 11 at 3:58 PM logoSUCCESS WITH PARSORTIX IN COLORECTAL CANCER - London South East (registration) (blog) - June 6 at 10:32 AM logoANGLE Reports Positive Results For Parsortix System In Colorectal Cancer - June 5 at 1:36 PM logoBeaufort Securities Reaffirms "Speculative Buy" Rating for ANGLE plc (AGL) - May 7 at 4:38 PM logoANGLE plc’s Microfluidic Liquid Biopsy Technology Featured in Research Presented at American Association of Cancer Researcher's Annual Meeting - April 3 at 3:35 PM logoANGLE plc (AGL) Stock Rating Reaffirmed by Beaufort Securities - March 31 at 1:52 PM logoHalf Year 2017 Angle PLC Earnings Release - Before Market Open - January 26 at 3:36 PM logoCould this small cap double after posting a £2.7m LOSS? - January 26 at 3:36 PM logoANGLE plc: Issue of Share Options - November 28 at 2:45 PM logoANGLE plc: Result of GM - November 24 at 3:01 PM logoGlobal Lender Equities First Holdings Returns Shares of ANGLE plc and Concludes Transaction in the United Kingdom - October 28 at 12:58 PM logoMD Anderson Cancer Center Research Demonstrates Clinical Applicability of ANGLE plc’s ‘Blood Biopsy’ Technology - August 2 at 8:08 AM logoANGLE plc: Use of Parsortix in GANNET53 Drug Trial - July 28 at 11:58 AM logoFull Year 2016 Angle PLC Earnings Release - Before Market Open - July 28 at 7:07 AM


Social activity is not available for this stock.


ANGLE plc (AGL) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff